Atlas Trials

Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Clinical trial NCT02716766 · COMPLETED

Trial details

NCT number
NCT02716766
Sponsor
The University of Hong Kong
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, HepatocellularSecondary
Start date
2016-03-01
Primary completion
2018-09-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.